

(51) International Patent Classification:  
C12N 15/86 (2006.01) A61K 48/00 (2006.01)

(21) International Application Number:  
PCT/EP2024/052670

(22) International Filing Date:  
02 February 2024 (02.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/443,289 03 February 2023 (03.02.2023) US

(71) Applicant: JANSSEN PHARMACEUTICA NV  
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: SPILLER, Krista; Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477 (US). SKARIAH, Geena; Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477 (US). HALDERMAN, Jonathan; Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477 (US).

(74) Agent: DUFFIELD, Stephen et al.; Carpmael's & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: GENE THERAPY VECTORS FOR USE IN PARKINSON'S DISEASE




Figure 1A

(57) Abstract: Disclosed herein are recombinant gene therapy vectors comprising a PTEN-induced kinase 1 (PINK1) encoding gene that is operatively linked to a promoter and methods of using the recombinant therapy vectors for inhibiting, reducing, or delaying degeneration or death of neurons of a subject.